A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro) in Growth Hormone Treatment naive Pre-pubertal Children With Growth Hormone Deficiency naive Pre-pubertal Children With Growth Hormone Deficiency
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 03 May 2017 Planned End Date changed from 17 Apr 2020 to 2 Oct 2020.
- 17 Feb 2017 Planned End Date changed from 1 Apr 2020 to 17 Apr 2020.
- 17 Feb 2017 Planned primary completion date changed from 1 Apr 2020 to 17 Apr 2020.